How US & UK retailers are embracing ASX listed CBD products
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
CBD may not yet be approved for sale in Australian stores but this doesn't mean Australian listed companies aren't pursuing the offshore market opportunity where regulations have paved a path for this growing industry.
Elixinol Global Limited (ASX:EXL) and Creso Pharma Limited (ASX:CPH) are accelerating their global exposure, and providing evidence for us to wonder - how long will it be until Australians can purchase the same products in their own neighbourhood?
While both companies have operations across multiple cannabis verticals, images of products on shelves in America and the United Kingdom highlight how hemp and CBD are hitting the mainstream.
A report by the World Health Organisation (WHO) last year showed CBD may help treat symptoms relating to Alzheimer’s Disease, Parkinson’s Disease, MS, pain, anxiety, depression, cancer and diabetic complications, but regulation regarding its use varies around the world.
Elixinol Global's recent investor presentation in May pictured its products in Safeway (owned by Albertsons) retail store in America. The company expects its products to rollout to 330 stores initially but is eyeing exposure across up to 1,000 stores.
"In the US, we are experiencing products on the back of growing consumer demand. We are very excited to receive our first order from Albertsons, one of the largest national retailers in the US," said Elixinol Global CEO Paul Benhaim.
Elixinol Global also signed significant retail agreements over the quarter for the UK which will see its CBD products advertised on TV and stocked on shelves in major retail stores and pharmacies in the coming months.
According to Paul Benhaim, "We see similar opportunities across many of the global markets that we are currently operating in, with ongoing discussions expected to lead to further agreements over the coming quarters."
Creso Pharma Limited (ASX:CPH) has also just celebrated its debut on to retail shelves, securing distribution of its unique CBD hemp-based, human health nutraceutical product cannaQIX® in two major retailers in the United Kingdom, Boots and Holland & Barrett International.
The distribution deal is a milestone for Creso Pharma as it represents the accelerating expansion and commercialisation of its product cannaQIX® which is being sold under the Pharmacare umbrella brand Naturopathica and product name Naturopathica CBD Lozenges.
“Accelerating the commercialization of cannaQIX® through distribution to the UK’s largest retailers is an exciting milestone for Creso Pharma. Our partnership with Pharmacare Europe has proved successful and been validated by significant distribution with recognised and respected retailers Boots and Holland & Barrett," said Creso Pharma’s CEO and Co‐Founder Dr. Miri Halperin Wernli.
The product cannaQIX® offers consumers a safe and effective certified Food Supplement with CBD which has broad market access without the need for medical prescription.
The operational milestone for Creso Pharma is also significant in the light of the recent AUD $122 million takeover offer it received from PharmaCielo Limited (TSXV: PCLO) last month.
According to the Cannabis Trades Association UK, the number of cannabidiol consumers increased from 125,000 in 2017 to 250,000 in 2018 in the United Kingdom.
In America, Cowen & Co. recently reported almost 7% of Americans are using CBD which is projected to grow to 10% of Americans by 2025. The investment research firm says the market already generates as much as $2 billion in sales which could grow to $16 billion by 2025.
While potential users of CBD will have to wait on the sidelines in Australia for now, investors in these companies are monitoring global regulatory developments and the anticipated expansion of product on shelves.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.